Jpmorgan Chase & CO Karuna Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$161.01 - $317.85 $591,711 - $1.17 Million	-3,675 Reduced 10.74%	30,552 $9.67 Million
Q3 2023 Nov 14, 2023	SELL	$164.66 - $218.08 $4.53 Million - $6 Million	-27,516 Reduced 44.57%	34,227 $5.79 Million
Q2 2023 Aug 11, 2023	BUY	$176.32 - $240.22 $1.6 Million - $2.18 Million	9,086 Added 17.26%	61,743 $13.4 Million
Q1 2023 May 18, 2023	BUY	$161.33 - $204.36 $6.69 Million - $8.48 Million	41,481 Added 371.16%	52,657 $9.56 Million
Q1 2023 May 11, 2023	SELL	$161.33 - $204.36 $4.1 Million - $5.2 Million	-25,436 Reduced 69.47%	11,176 $2.03 Million

Q4 2022 Feb 13, 2023	BUY	$191.53 - $236.82 $634,921 - $785,058	3,315 Added 9.96%	36,612 $7.2 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $1.16 Million - $2.59 Million	9,331 Added 38.93%	33,297 $7.49 Million
Q2 2022 Aug 11, 2022	BUY	$93.97 - $143.33 $352,199 - $537,200	3,748 Added 18.54%	23,966 $3.03 Million
Q1 2022 May 11, 2022	BUY	$98.9 - $132.37 $328,051 - $439,071	3,317 Added 19.63%	20,218 $2.56 Million
Q4 2021 Feb 10, 2022	BUY	$110.64 - $159.4 $153,568 - $221,247	1,388 Added 8.95%	16,901 $2.21 Million
Q3 2021 Nov 12, 2021	BUY	$101.2 - $125.87 $1.57 Million - $1.95 Million	15,513 New	15,513 $1.9 Million

333K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.